CSBio CSBio

X
[{"orgOrder":0,"company":"Regent Pacific","sponsor":"Wanbang Biopharmaceuticals","pharmaFlowCategory":"D","amount":"$4.0 million","upfrontCash":"Undisclosed","newsHeadline":"Regent Pacific's Strategic Partner Receives Approval from NMPA to Submit IND Application","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Approved","country":"HONG KONG","productType":"Small molecule","productStatus":"Approved","date":"December 2020","url1":"","url2":"","graph1":"Small molecule","graph2":"Regent Pacific"}]

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Loading...
Filters Filter
×
FILTER:
filter News Type
    filter Company
      filter Product Type
        filter Deal Size
          filter Upfront Payment

            Active Filter(s):

            Product Type

            Companies

            Details:

            Under the License Agreement Regent Pacific is now entitled to receive a payment of approximately HK$6.24 million from Wanbang Pharmaceutical, which is payable within 30 business days. NMPA will now formally review Senstend™ for Clinical Trial Approval.

            Lead Product(s): Lidocaine,Prilocaine

            Therapeutic Area: Psychiatry/Psychology Product Name: Senstend

            Highest Development Status: Approved Product Type: Small molecule

            Partner/Sponsor/Collaborator: Wanbang Biopharmaceuticals

            Deal Size: $4.0 million Upfront Cash: Undisclosed

            Deal Type: Licensing Agreement December 02, 2020

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity
            Post Enquiry
            POST ENQUIRY